Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 94 Small Cell Lung Carcinoma 76 Neuroblastoma 44 Carcinoma, Ovarian Epithelial 43 Fallopian Tube Neoplasms 41 Lung Neoplasms 39 Neoplasms 29 Uterine Cervical Neoplasms 26 Leukemia 20 Brain Neoplasms 18 Leukemia, Myeloid, Acute 17 Recurrence 16 Sarcoma 15 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Neoplasm Metastasis 13 Lymphoma 12 Central Nervous System Neoplasms 12 Retinoblastoma 11 Glioma 11 Carcinoma, Non-Small-Cell Lung 11 Sarcoma, Ewing 10 Unspecified Adult Solid Tumor, Protocol Specific 8 Neuroectodermal Tumors, Primitive, Peripheral 8 Myelodysplastic Syndromes 8 Medulloblastoma 8 Endometrial Neoplasms 8 Burkitt Lymphoma 8 Lymphoma, Follicular 7 Leukemia, Myelomonocytic, Chronic 7 Blast Crisis 7

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Disease × Topotecan × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡